Lymphoma Canada applauds the recent reimbursement announcements by the provinces of Alberta, Saskatchewan and Ontario for their decisions to fund Treanda (bendamustine)
Lymphoma Canada applauds the recent reimbursement announcements by the provinces of Alberta, Saskatchewan and Ontario for their decisions to fund Treanda (bendamustine) as a new front-line treatment of iNHL and MCL when used in combination with rituximab. The provinces also decided to fund Treanda (bendamustine) for the treatment of relapsed and refractory iNHL and MCL as recommended by the pan-Canadian Oncology Drug Review (pCODR) agency (1).
Treanda (bendamustine) is also currently reimbursed on a case-by-case basis in British Columbia, Manitoba and in the Atlantic provinces. It is expected that formal funding announcements will follow in the very near future.
It is now a critical time for the province of Quebec to follow suit and fund this highly awaited and necessary new treatment regimen for patients with iNHL and MCL.
1- http://www.pcodr.ca/idc/groups/pcodr/documents/pcodrdocument/pcodr-treandanhl-fn-rec.pdf
